Evidence map›Paper›PMID 22733743›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2012

Crystal structure and biochemical studies of the trans-acting polyketide enoyl reductase LovC from lovastatin biosynthesis.

Brian D Ames, Chi Nguyen, Joel Bruegger, Peter Smith, Wei Xu, Suzanne Ma, Emily Wong, Steven Wong, Xinkai Xie, Jesse W-H Li and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed
5.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 94 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Kupyaphores are zinc homeostatic metallophores required for colonization ofProceedings of the National Academy of Sciences of the United States of America · 2022
    Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. A comprehensive catalogue of polyketide synthase gene clusters in lichenizing fungi.Journal of industrial microbiology & biotechnology · 2018
    Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 3 institutions in 2 countries.

Brian D AmesDepartment of Molecular Biology and Biochemistry, University of California, Irvine, CA 92697, USA.
Chi Nguyen
Joel Bruegger
Peter Smith
Wei Xu
Suzanne Ma
Emily Wong
Steven Wong
Xinkai Xie
Jesse W-H Li
John C Vederas
Yi Tang
Shiou-Chuan Tsai
University of California, Irvine · USUniversity of California, Los Angeles · USUniversity of Alberta · CA

Funding

The Molecular Basis of Regio-Specificity in Fungal Polyketide SynthaseR01GM100305 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI BURKART, MICHAEL D., TSAI, SHIOU-CHUAN · 2012 to 2015
$1.6M
The Ketoreduction and Cyclization of Aromatic Polyketide BiosynthesisR01GM076330 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI TSAI, SHIOU-CHUAN · 2007 to 2011
$1.3M
Metabolic and Biosynthetic Engineering of Statin-Producing Filamentous FungusR01GM089998 · NIGMS · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI TANG, YI · 2009 to 2011
$414k
NIGMS NIH HHS R01 GM076330NIGMS NIH HHS R01GM076330NIGMS NIH HHS R01 GM089998NIGMS NIH HHS R01 GM100305
6 · The paper itself

Abstract

Lovastatin is an important statin prescribed for the treatment and prevention of cardiovascular diseases. Biosynthesis of lovastatin uses an iterative type I polyketide synthase (PKS). LovC is a trans-acting enoyl reductase (ER) that specifically reduces three out of eight possible polyketide intermediates during lovastatin biosynthesis. Such trans-acting ERs have been reported across a variety of other fungal PKS enzymes as a strategy in nature to diversify polyketides. How LovC achieves such specificity is unknown. The 1.9-Å structure of LovC reveals that LovC possesses a medium-chain dehydrogenase/reductase (MDR) fold with a unique monomeric assembly. Two LovC cocrystal structures and enzymological studies help elucidate the molecular basis of LovC specificity, define stereochemistry, and identify active-site residues. Sequence alignment indicates a general applicability to trans-acting ERs of fungal PKSs, as well as their potential application to directing biosynthesis.

Indexed as

AspergillusAtherosclerosisCandida tropicalisCatalytic DomainChromatography, GelCrystallography, X-RayHumansLovastatinMolecular ConformationMutationNADPPolyketide SynthasesProtein ConformationProtein Structure, QuaternaryProtein Structure, TertiaryStatic ElectricityLovastatinNADPPolyketide Synthases

Identifiers

PMID22733743
PMCPMC3396468
OpenAlexW1970922250

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.